Codexis, Inc. (CDXS)
After hours:
| Previous Close | 3.9400 |
| Open | 3.9900 |
| Bid | 4.0500 x 2900 |
| Ask | 4.1600 x 1200 |
| Day's Range | 3.9200 - 4.1500 |
| 52 Week Range | 3.7900 - 22.2200 |
| Volume | |
| Avg. Volume | 638,366 |
| Market Cap | 271.944M |
| Beta (5Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4040 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.25 |
- Simply Wall St.
Codexis, Inc.'s (NASDAQ:CDXS) Intrinsic Value Is Potentially 24% Below Its Share Price
Key Insights The projected fair value for Codexis is US$2.93 based on 2 Stage Free Cash Flow to Equity Codexis' US$3.88...
- GlobeNewswire
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 43,403 shares of Codexis’ common stock and (ii) restricted stock units (RSUs) for 9,723 shares of Codexis common stock as induceme
- GlobeNewswire
Codexis to Participate in Cowen 43rd Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, will participate in a panel discussion titled, “SynBio & AI Driven Drug Discovery,” taking place on Mo
